Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed

GSK Yet To Submit Application For Sotrovimab In India

25 Jun 2021

Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.

Vial of monoclonal antibodies — Monoclonal Antibody Therapy For COVID-19 Might Be Threatened By New SARS-CoV-2 Variants • Source: Alamy

India recently classified the Delta Plus coronavirus variant, originally found in Europe, as a variant of concern after the Indian SARS-CoV-2 Genomic Consortia (INSACOG), a network of labs to study and monitor genome sequencing and virus variation of circulating strains of SARS-CoV-2, said the variant has higher transmissibility and stronger binding to receptors of lung cells.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Dollar Weakness, Tariffs, Biosimilars In J&J’s Q1 Mix

22 Apr 2025

• By Andy Smith

Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

22 Apr 2025

• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.